LY305

LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.^[1][2][3]

LY305

Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile
CAS Number	1430230-83-3
PubChem CID	71543393
ChemSpider	58921204
ChEMBL	ChEMBL3764185
Chemical and physical data
Formula	C14H17ClN2O2
Molar mass	280.75 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1Cl)C#N)N[C@@H]2CCC[C@@]2(C)O
InChI InChI=1S/C14H17ClN2O/c1-9-11(6-5-10(8-16)13(9)15)17-12-4-3-7-14(12,2)18/h5-6,12,17-18H,3-4,7H2,1-2H3/t12-,14-/m1/s1 Key:CXFSVKGROITHRY-TZMCWYRMSA-N

See also

• Compound 2f (SARM)